34 results about "Myelin body formation" patented technology

The invention discloses an IL7R gene-deleted zebra fish mutant and a preparation method thereof. The construction of the IL7R gene-deleted zebra fish mutant is realized through a CRISPR / Cas9 technology. Moreover, the invention also discloses application of the IL7R gene-deleted zebra fish mutant; a mutant model provided by the invention can be used for studying an effect of IL7R in the nervous system development and myelination.

The present invention disclosed methods of inducing maturation of oligodendrocyte cells. A method of inducing myelination in a patient suffering from demyelination is also disclosed

The invention relates to methods and compositions for treating demyelination and / or dysmyelination and / or promoting remyelination of neurons and / or preventing the development of myelin-related diseases by administering to a subject in need thereof an effective amount (either therapeutic or prophylactic) of an elemental gold crystal nanosuspension.

The invention relates to a nutritional composition for infants and young children, such as an infant formula or follow-on formula or growing up milk, preferably an infant formula, and comprising a phospholipid, a metabolic precursor and / or a metabolite thereof. The phospholipid promotes and / or supports an optimal myelination trajectory in the brain, such trajectory being close to that observed ininfants fed exclusively with human breast milk (HBM). The infants or young children can be between 0 and 60 months, preferably between 0 and 12 months of age.

The invention relates to a nutritional composition for infants and young children, such as an infant formula or follow-on formula or growing up milk, preferably an infant formula, and comprising a fatty acid derivative or mixtures thereof, for example ARA and / or DHA. The a fatty acid derivative or a mixture thereof, for example ARA and / or DHA promotes and / or supports an ideal myelination trajectory in the brain, such trajectory being close to that observed in infants fed exclusively with human breast milk (HBM). The infants or young children can be between 0 and 60 months, preferably between 0and 12 months of age.

The present application relates to a method of promoting the production of oligodendrocytes from oligodendrocyte precursor cells by enhancing its survival and / or maturation, comprising administering to the cell an effective amount of an agent that enhances and / or induces the accumulation of [Delta] 8, 9-unsaturated sterol intermediates of the cholesterol biosynthetic pathway in oligodendrocyte precursor cells.

The invention belongs to the technical field of data detection, and discloses a method for measuring the myelination of the central nervous system by Gm7237. The drug used to treat CNS demyelination is gastrodin, which can significantly promote the formation of CNS myelination in a mouse model in vivo . By using high-throughput sequencing analysis, the present invention discovers the key long non-coding RNA Gm7237 that can enhance CNS myelination and is up-regulated by GAS. Through bioinformatics analysis and experimental verification, it was revealed that microRNA‑142a and its target myelin gene regulatory factor (MRF) were directly regulated by Gm7237. demonstrated that the Gm7237 / miR‑142a / MRF axis is a key pathway involved in CNS myelination mediated by GAS. The results of the present invention not only provide novel agents for the treatment of CNS demyelination, but also provide a molecular basis for GAS-promoted CNS myelination.

The present invention relates to a topical agent that binds specifically to myelin basic protein and its method of use and determining myelination in the subject by detecting the agent present in the subject. A kit containing the agent or its derivatives for use in detecting myelin basic protein is also provided.

This invention provides novel methods for treating or ameliorating symptoms of demyelinating diseases such as multiple sclerosis. The methods involve administering to subjects in need of treatment a pharmaceutical composition that contains a therapeutically effective amount of taurine and also a compound that induces oligodendrocyte precursor cell (OPC) differentiation (e.g., T3, benztropine, clemastine or miconazole). Some of the methods additionally involve administration to the subject a known agent for treating demyelinating diseases (e.g., SIP receptor agonists) or a known disease modifying drug. The invention also provides methods for increasing myelination and methods for promoting OPC differentiation into oligodendrocytes. These methods entail contacting a population of OPCs with a combination of taurine and a known OPC differentiation-inducing agent such as T3, clemastine, benztropine or miconazole.

A synthetic nutritional composition comprising a mineral for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and / or brain structure, and / or brain connectivity, and / or intellectual potential and / or cognitive potential and / or learning potential and / or cognitive functioning in a subject, in particular a formula fed subject.

Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

The invention relates to a nutritional composition for infants and young children, such as an infant formula or follow-on formula or growing up milk, preferably an infant formula, and comprising a vitamin or mixtures thereof. The vitamins promotes and / or supports an ideal myelination trajectory in the brain, such trajectory being close to that observed in infants fed exclusively with human breastmilk (HBM). The infants or young children can be between 0 and 60 months, preferably between 0 and 12 months of age.

A synthetic nutritional composition comprising a vitamin for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and / or brain structure, and / or brain connectivity, and / or intellectual potential and / or cognitive potential and / or learning potential and / or cognitive functioning in a subject, in particular a formula fed subject.

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is caused by dominant inactivating mutations in the colony stimulating factor receptor 1 (CSF1R) kinase domain. GM-CSF haploinsufficiency corrects olfactory, cognitive and emotional functions lost in Csf1r+ / − mice. This correlates with the correction of microgliosis and microglial functions resulting in improvement of myelination and rescue of neurogenesis. However, GM-CSF haploinsufficiency fails to correct the motor deficits of Csf1r+ / − mice and cerebellar microgliosis. The present invention discloses methods and compositions using GM-CSF as a suitable therapeutic target to inhibit in amelioration of the cognitive impairments in ALSP and other in conditions involving inflammatory activation of microglia and macrophages, such as AD, ALS, multiple sclerosis, and hippocampal inflammation following radiation therapy. Treatment with GM-CSF inhibitors is beneficial in ALSP, as adult neurogenesis is important for memory, olfaction and prevention of anxiety / depression and early initiation of such treatment in carriers of CSF1R mutations may increase effectiveness. Balancing the actions of CSF-1R and GM-CSF signaling are necessary to preserve olfaction, cognition and emotional balance in aged mice. This balance is likely altered in many neurodegenerative diseases in which activated microglia contribute to the pathology.

The present invention discloses a method of identifying agents that affect maturation and survival of oligodendrocytes or myelination of neuronal cells using ex-vivo differentiated embryonic stem cells.

A synthetic nutritional composition comprising a mineral for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and / or brain structure, and / or brain connectivity, and / or intellectual potential and / or cognitive potential and / or learning potential and / or cognitive functioning in a subject, in particular a formula fed subject.